Cataño-Jaramillo M L, Jaramillo-Bustamante J C, Florez I D
Hospital General Medellín, Medellín, Colombia.
Hospital General Medellín, Medellín, Colombia; Department of Pediatrics, University of Antioquia, Medellín, Colombia.
Med Intensiva (Engl Ed). 2020 Nov 6. doi: 10.1016/j.medin.2020.09.008.
To compare the safety and effectiveness of Continuous Positive Airway Pressure (CPAP) vs. High Flow Nasal Cannula (HFNC) to prevent therapeutic failure and the need of invasive ventilation in children with acute moderate-severe bronchiolitis.
A systematic review and meta-analysis.
Medline, Embase, Lilacs, Cochrane and gray literature (May 2020) was performed.
Randomized clinical trials patients with moderate to severe bronchiolitis.
Therapeutic failure, need for invasive ventilation, adverse events, length of PCCU and of hospital stay.
The quality of the studies was assessed with the Cochrane risk and bias tool. We conducted meta-analysis using fixed effect model and random effects model.
Three RCTs were included. Showed less risk of therapeutic failure with CPAP compared with HFNC (RR=0.7; 95%CI 0.5-0.99) developed hours later in patients with CPAP (MD=3.16; 95%CI 1.55-4.77). We did not find differences in other outcomes, such as need of invasive ventilation (RR=0.60; 95%CI 0.25-1.43), apnea (RR=0.40; 95%CI 0.08-1.99), or number of days in the intensive care unit (MD=0.02; 95%CI -0.38 to 0.42), and length of hospitalization (MD=-1.00; 95%IC -2.66 to 0.66). Adverse events (skin lesions) were more common with CPAP (RR 2.47; 95%CI 1.17-5.22).
In moderate/severe bronchiolitis CPAP demonstrated a lower risk of therapeutic failure and a longer time to failure. But more adverse events like nasal injury. There were no differences in other variables.
比较持续气道正压通气(CPAP)与高流量鼻导管吸氧(HFNC)预防急性中重度细支气管炎患儿治疗失败及有创通气需求的安全性和有效性。
系统评价和荟萃分析。
检索了Medline、Embase、Lilacs、Cochrane及灰色文献(2020年5月)。
中重度细支气管炎的随机临床试验患者。
治疗失败、有创通气需求、不良事件、儿科重症监护病房(PCCU)住院时间及住院总时长。
采用Cochrane风险偏倚工具评估研究质量。使用固定效应模型和随机效应模型进行荟萃分析。
纳入三项随机对照试验(RCT)。结果显示,与HFNC相比,CPAP治疗失败风险更低(相对危险度[RR]=0.7;95%置信区间[CI] 0.5 - 0.99),且CPAP治疗失败时间更晚(平均差[MD]=3.16;95%CI 1.55 - 4.77)。在其他结局方面未发现差异,如有创通气需求(RR=0.60;95%CI 0.25 - 1.43)、呼吸暂停(RR=0.40;95%CI 0.08 - 1.99)、重症监护病房住院天数(MD=0.02;95%CI -0.38至0.42)及住院时长(MD=-1.00;95%CI -2.66至0.66)。CPAP组不良事件(皮肤损伤)更常见(RR 2.47;95%CI 1.17 - 5.22)。
在中重度细支气管炎中,CPAP治疗失败风险更低且失败时间更长。但会出现更多如鼻损伤等不良事件。在其他变量方面无差异。